Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation
N. K. Hurlburt, Y.-H. Wan, A. B. Stuart, J. Feng, A. T. McGuire, L. Stamatatos, M. Pancera
Abstract
SARS-CoV-2 is a betacoronavirus virus responsible for the COVID-19 pandemic. Here, we determined the X-ray crystal structure of a potent neutralizing monoclonal antibody, CV30, isolated from a patient infected with SARS-CoV-2, in complex with the receptor binding domain (RBD). The structure reveals CV30s epitope overlaps with the human ACE2 receptor binding site thus providing the structural basis for its neutralization by preventing ACE2 binding.
02 /Specification & Classification
Click any tag to browse matching papers- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies
- Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2
S. A. Clark, L. E. Clark, … J. Abraham·bioRxiv·Nov 13, 2020
- A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD
- A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody
N. C. Wu, M. Yuan, … I. A. Wilson·bioRxiv·Sep 21, 2020
- Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection
- A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein
M. G. Joyce, R. S. Sankhala, … K. Modjarrad·bioRxiv·Mar 15, 2020